Business
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France, May 23, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncology
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/08fc87f4e3c4939b3c20a82ce69c38af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1uR01ekpTBxffAOX5jQouQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/08fc87f4e3c4939b3c20a82ce69c38af","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Injxc1Zk5wflyQY7uMX9HQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/08fc87f4e3c4939b3c20a82ce69c38af","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025.","length":158,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Long-term follow-up data from TELLOMAK study confirms the meaningful clinical activity in heavily pretreated SS patients with a global overall response rate (ORR) of 42.9% and an impressive median duration of response of 25.6 months.","length":234,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data also confirms meaningful activity in heavily pretreated MF patients with a global ORR of 19.6% and confirms that the anti-tumor activity is observed in all patients (KIR3DL2 ≥1% or < 1% at baseline).","length":207,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These compelling data, in a patient population with multiple prior systemic treatments strongly support the development of lacutamab for MF and SS.","length":147,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":746,"olType":false},{"type":"text","content":"MARSEILLE, France, May 23, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive fo...